<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02231905</url>
  </required_header>
  <id_info>
    <org_study_id>248.544</org_study_id>
    <nct_id>NCT02231905</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease</brief_title>
  <official_title>Open Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to Pramipexole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the safety, tolerability and effectiveness of a switching from Domin®
      (talipexole) tablet to BI Sifrol® (pramipexole) tablet in patients with Parkinson's disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who prematurely discontinued due to adverse event</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the sum of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (activities of daily living)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the sum of UPDRS Part III (motor examination)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Modified Hoehn &amp; Yahr scale</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Clinical global impression (CGI) of efficacy</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Blood Pressure, Pulse Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in electrocardiogram (ECG)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>BI-Sifrol®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI-Sifrol®</intervention_name>
    <arm_group_label>BI-Sifrol®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Parkinson's disease (included juvenile parkinsonism) and treated with
             talipexole (Domin®)

          2. Patients who present stable symptoms and maintain the doses of talipexole and other
             concomitant therapy for Parkinson's disease at least last 4 weeks

          3. Male or female patients aged 20 and over

          4. In or out-patients

          5. Patient's severity characterized as Stage 1 - 5 by Modified Hoehn &amp; Yahr scale

          6. Ability to provide written informed consent in accordance with the Good Clinical
             Practice (GCP), Good Post-marketing Surveillance Practice (GPMSP) and other relevant
             laws such as the Pharmaceutical Affairs Law

        Exclusion Criteria:

          1. History of hypersensitivity of pramipexole

          2. Psychiatric symptoms such as confusion, hallucination, delusion, agitation, delirium
             and abnormal behavior

          3. Subjective symptom derived from orthostatic hypotension

          4. Hypotension (systolic blood pressure; 100 mmHg or less)

          5. Complication such as clinically significant cardiac, renal and hepatic diseases

          6. Patients who drive a car, operate a machine, work on heights or engage in other
             hazardous activities

          7. Pregnant, possibly pregnant or female in lactation

          8. Patients who are participating in other drug studies or who receive other
             investigational drugs within last 3 months before enrolled this study

          9. Other than above, those who judged by the investigator or sub-investigator to be
             inappropriate as for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2014</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Talipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

